Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Sanmartin Fernández M, Arribas F, Masjuan J, Barrios V, Cosin-Sales J, Freixa-Pamias R, Recalde E, Pérez-Cabeza AI, Manuel Vázquez Rodríguez J, Ràfols Priu C, Anguita Sánchez M, Lip GYH, Marin F. Esteve-Pastor MA, et al. Among authors: rafols priu c. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):38-46. doi: 10.1093/ehjcvp/pvac060. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 36318457
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study.
Anguita Sánchez M, Marín F, Masjuan J, Cosín-Sales J, Vázquez Rodríguez JM, Barrios V, Barón-Esquivias G, Lekuona I, Pérez-Cabeza AI, Freixa-Pamias R, Parra Jimenez FJ, Monzer Khanji Khatib M, Rafols Priu C, Sanmartín Fernández M. Anguita Sánchez M, et al. Among authors: rafols priu c. Cardiol J. 2022;29(6):936-947. doi: 10.5603/CJ.a2022.0091. Epub 2022 Oct 6. Cardiol J. 2022. PMID: 36200548 Free PMC article.
Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
Sanmartín Fernández M, Anguita Sánchez M, Arribas F, Barón-Esquivias G, Barrios V, Cosin-Sales J, Esteve-Pastor MA, Freixa-Pamias R, Lekuona I, Pérez-Cabeza AI, Ureña I, Vázquez Rodríguez JM, Rafols Priu C, Marin F. Sanmartín Fernández M, et al. Among authors: rafols priu c. Cardiol J. 2022;29(4):601-609. doi: 10.5603/CJ.a2022.0044. Epub 2022 May 27. Cardiol J. 2022. PMID: 35621092 Free PMC article.